DB:3NH

Stock Analysis Report

Executive Summary

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Novoheart Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3NH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.6%

3NH

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

93.3%

3NH

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: 3NH exceeded the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: 3NH exceeded the German Market which returned 2.9% over the past year.


Shareholder returns

3NHIndustryMarket
7 Day-8.6%-11.1%-9.1%
30 Day-8.4%-12.8%-7.2%
90 Day58.4%-9.6%-6.5%
1 Year93.3%93.3%-2.7%-2.9%6.1%2.9%
3 Yearn/a25.8%24.4%3.5%-5.6%
5 Yearn/a1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Novoheart Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Novoheart Holdings undervalued compared to its fair value and its price relative to the market?

3.82x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3NH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3NH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3NH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 3NH is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3NH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3NH is overvalued based on its PB Ratio (3.6x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Novoheart Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novoheart Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Novoheart Holdings performed over the past 5 years?

-32.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3NH is currently unprofitable.

Growing Profit Margin: 3NH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3NH is unprofitable, and losses have increased over the past 5 years at a rate of -32.7% per year.

Accelerating Growth: Unable to compare 3NH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3NH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 3NH has a negative Return on Equity (-24.72%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Novoheart Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 3NH's short term assets (CA$20.5M) exceed its short term liabilities (CA$1.6M).

Long Term Liabilities: 3NH's short term assets (CA$20.5M) exceed its long term liabilities (CA$958.0K).


Debt to Equity History and Analysis

Debt Level: 3NH is debt free.

Reducing Debt: 3NH had no debt 5 years ago.


Balance Sheet

Inventory Level: 3NH has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 3NH's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3NH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 3NH has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -22.2% each year


Next Steps

Dividend

What is Novoheart Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 3NH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 3NH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3NH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3NH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3NH's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Ronald Li (48yo)

4.1yrs

Tenure

CA$455,113

Compensation

Dr. Ronald Li Sc.(Hons), Ph.D., is Scientific Co-Founder at Novoheart Holdings Ltd. and also has been its Chief Executive Officer since 2016 and has served as a Director since September 27, 2017. Dr. Li se ...


CEO Compensation Analysis

Compensation vs Market: Ronald's total compensation ($USD340.60K) is about average for companies of similar size in the German market ($USD419.45K).

Compensation vs Earnings: Ronald's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ronald Li
Scientific Co-Founder4.1yrsCA$455.11kno data
Camie Chan
Interim CFO2.4yrsCA$442.50k0.19% CA$167.8k
Bill Williams
Senior Vice President of Commercial Operations1.5yrsCA$420.15kno data
Bernard Fermini
Chief Research & Development Officer1.4yrsCA$400.13k0.042% CA$36.9k
Kevin Costa
Chief Scientific Officer & Scientific Co-Founder0yrsCA$456.03k0.41% CA$359.5k
Michelle Khine
Scientific Co-Founder & Member of Scientific Advisory Board0yrsno datano data

1.5yrs

Average Tenure

48yo

Average Age

Experienced Management: 3NH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ronald Li
Scientific Co-Founder4.1yrsCA$455.11kno data
Camie Chan
Interim CFO2.4yrsCA$442.50k0.19% CA$167.8k
Michelle Khine
Scientific Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Tong Chiu
Independent Director2.4yrsno data1.05% CA$912.0k
Gordon Tomaselli
Member of Scientific Advisory Board0yrsno datano data
James Topham
Independent Director2.4yrsno datano data
Kam-Sing Ma
Independent Chairman of the Board2.4yrsno datano data
Tin Duk Chang
Independent Director2.4yrsno data3.29% CA$2.9m
Ngan Ng Yu Ying
Independent Director0.7yrsno data3.67% CA$3.2m
Leslie Tung
Member of Scientific Advisory Board0yrsno datano data

2.4yrs

Average Tenure

48yo

Average Age

Experienced Board: 3NH's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 3NH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27%.


Top Shareholders

Company Information

Novoheart Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Novoheart Holdings Inc.
  • Ticker: 3NH
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$128.276m
  • Listing Market Cap: CA$86.947m
  • Shares outstanding: 188.64m
  • Website: https://www.novoheart.com

Number of Employees


Location

  • Novoheart Holdings Inc.
  • 595 Burrard Street
  • Suite 2600
  • Vancouver
  • British Columbia
  • V7X 1L3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVHTSXV (TSX Venture Exchange)YesNew Common SharesCACADOct 2017
3NHDB (Deutsche Boerse AG)YesNew Common SharesDEEUROct 2017
PFRC.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDOct 2017

Biography

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 23:56
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.